Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgrades Annexon (NASDAQ:ANNX) from Market Underperform to Market Perform.
Read original at benzingaStocks · News reference
Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 12:17 PM
- Checked
- Aug 6, 2026, 12:17 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Annexon, Inc. (ANNX)
Filed: 2026-08-12 AccNo: 0001193125-26-345672 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarAnnexon Q2 EPS $(0.28) Misses $(0.24) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34) per share from the
Read original at benzingaAnnexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy
Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today
Read original at benzinga